Phathom Pharmaceuticals secures FDA approval for VOQUEZNA to treat non-erosive GERD in adults

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical innovator in gastrointestinal (GI) therapeutics, has received approval from the U.S. Food and Drug Administration (FDA) for VOQUEZNA 10 mg tablets, indicated for the treatment of Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD) in adults. The milestone marks the therapy’s third FDA approval, following prior authorizations for the healing and maintenance of healing in Erosive Esophagitis and for use in combination with antibiotics to eradicate Helicobacter pylori infection.

This latest greenlight makes VOQUEZNA the first and only treatment from a new class of acid suppression therapy available to the largest segment of the U.S. GERD population. The condition, characterized by reflux symptoms without visible damage to the esophagus, is estimated to affect approximately 45 million adults in the United States, representing the majority of GERD cases.

Why is the FDA approval of VOQUEZNA for non-erosive GERD considered a breakthrough in acid suppression therapy?

For decades, U.S. patients with Non-Erosive GERD have had access only to established acid-suppressing drugs such as proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs). While these treatments are effective for many, a significant portion of patients report incomplete relief from heartburn symptoms. Phathom’s VOQUEZNA, based on the potassium-competitive acid blocker (PCAB) vonoprazan, introduces a novel mechanism of action that offers rapid, potent, and sustained acid suppression.

According to Phathom Pharmaceuticals’ President and Chief Executive Officer Terrie Curran, the approval signals a new era for GERD therapy. She noted that the milestone provides immediate access to a first-in-class option capable of delivering 24-hour heartburn-free periods, both during the day and at night. Curran emphasized the company’s commitment to the broader GERD community and voiced optimism that VOQUEZNA could help change treatment paradigms in the field.

What does clinical evidence from the PHALCON-NERD-301 trial reveal about VOQUEZNA’s efficacy and safety?

The FDA decision is grounded in robust Phase 3 data from the PHALCON-NERD-301 study, a multicenter, randomized, double-blind, placebo-controlled trial evaluating VOQUEZNA in 772 adults with Non-Erosive GERD. Participants received either VOQUEZNA 10 mg once daily or placebo for four weeks.

Results showed that VOQUEZNA achieved a statistically significant 45% increase in the proportion of 24-hour heartburn-free days compared to placebo. The improvement was evident as early as the first week of treatment and was maintained throughout the study period. The therapy demonstrated a safety profile consistent with prior trials in other indications, with the most common adverse events being mild gastrointestinal symptoms and headache.

Colin W. Howden, M.D., Professor Emeritus at the University of Tennessee College of Medicine, commented that many Non-Erosive GERD patients remain symptomatic despite existing options. He stated that the trial data confirm VOQUEZNA’s potential to provide rapid and meaningful symptom relief for this underserved group.

How significant is non-erosive GERD in the overall landscape of gastrointestinal diseases?

Non-Erosive GERD is the most prevalent form of GERD in the United States. Unlike erosive disease, where acid reflux causes visible damage to the esophageal lining, this condition presents without mucosal injury but with persistent symptoms such as heartburn and regurgitation. It can significantly impair quality of life, disturb sleep, and affect productivity.

Historically, the management of Non-Erosive GERD has been challenging. PPIs have been the mainstay of therapy but can take days to achieve full effect and may not fully address nighttime symptoms. This gap has driven the search for therapies with faster onset, longer duration, and improved symptom control across the 24-hour cycle. VOQUEZNA’s pharmacological profile, offering acid suppression within hours of administration and sustained through the dosing period, aims to fill this clinical need.

How does VOQUEZNA’s mechanism of action differ from traditional PPIs and H2 receptor antagonists?

VOQUEZNA’s active ingredient, vonoprazan, belongs to the potassium-competitive acid blocker class. Unlike PPIs, which require activation in the acidic environment of the stomach and take several days to reach full efficacy, PCABs inhibit the gastric hydrogen-potassium ATPase enzyme directly and reversibly. This leads to faster acid suppression and more consistent pH control over a 24-hour period.

H2 receptor antagonists, another widely used class, act by blocking histamine-mediated stimulation of acid secretion. However, their effectiveness may diminish over time due to tachyphylaxis. PCABs like vonoprazan have shown durable acid suppression without this limitation in clinical studies.

What does this approval mean for Phathom Pharmaceuticals’ commercial strategy in the United States?

The addition of Non-Erosive GERD to VOQUEZNA’s label expands Phathom Pharmaceuticals’ potential market reach significantly. GERD affects up to 20% of the U.S. adult population, and the Non-Erosive subtype represents the majority. By offering a differentiated product that addresses an area of persistent unmet need, the biopharmaceutical developer strengthens its competitive position in the gastrointestinal therapeutics segment.

The company’s commercial strategy includes physician education initiatives to raise awareness about the PCAB class and its clinical advantages. The U.S. launch will also leverage patient access programs to facilitate adoption. Given that VOQUEZNA is already indicated for other acid-related disorders, the expanded label allows for broader prescribing opportunities across gastroenterology and primary care practices.

How does the approval align with broader trends in gastrointestinal drug development?

The gastrointestinal drug market has seen limited innovation in acid suppression therapies since the widespread adoption of PPIs in the 1980s and 1990s. Recent years have brought renewed interest in therapies that can offer more complete symptom control and faster relief. This trend is driven by patient demand, the need to address partial responders, and the competitive pressure for differentiation in a mature market.

Phathom Pharmaceuticals’ success with VOQUEZNA follows a global pattern in which PCABs have gained traction in Asia, particularly Japan, where vonoprazan has been in use for multiple indications. The U.S. market entry for Non-Erosive GERD adds momentum to the adoption of this drug class in Western markets.

What are the potential implications for patients and healthcare providers?

For patients, the approval offers a new option that may improve daily comfort, sleep quality, and overall health-related quality of life. For healthcare providers, it provides a first-in-class therapy supported by high-level clinical evidence, potentially simplifying treatment decisions for Non-Erosive GERD cases that are refractory to existing regimens.

Phathom’s VOQUEZNA is now available by prescription in the United States, with dosing recommendations specified in the approved label. The therapy is expected to be incorporated into treatment algorithms as clinicians become more familiar with PCABs’ benefits and safety considerations.